Corticotropin-releasing hormone receptor antagonists

European Journal of Endocrinology, Supplement

Volumn 155, Issue 1, 2006, Pages

  Zoumakis, E ^a   Grammatopoulos, D K ^b   Chrousos, G P ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 2 [N ETHYL N (4 ISOPROPYL 2 METHYLTHIOPHENYL)AMINO] 6 METHYLPYRIMIDINE; 5 CHLORO 4 [N (CYCLOPROPYLMETHYL) N PROPYLAMINO] 2 METHYL 6 (2,4,6 TRICHLOROANILINO)PYRIMIDINE; ANTALARMIN; BUPRENORPHINE; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1 ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2 ANTAGONIST; NBI 35965;

ACUTE DISEASE; ANXIETY DISORDER; AUTONOMIC NERVOUS SYSTEM; BEHAVIOR; BINDING SITE; BRAIN; CHRONIC DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DISEASE COURSE; DRUG MECHANISM; ENDOCRINE SYSTEM; HUMAN; IMMUNE RESPONSE; INFLAMMATORY DISEASE; NERVE DEGENERATION; NONHUMAN; OPIATE ADDICTION; PATHOPHYSIOLOGY; PREMATURE LABOR; SLEEP DISORDER; STRESS;

EID: 33845446360     PISSN: 08044635     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02259     Document Type: Conference Paper

References (98)

1. Vale W, Spiess J, Rivier C & Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981 213 1394-1397.
2. Brown MR, Rivier C & Vale W. Central nervous system regulation of adrenocorticotropin secretion: role of somatostatins. Endocrinology 1984 114 1546-1549.
3. Jingami H, Mizuno N, Takahashi H, Shibahara S, Furutani Y, Imura H & Numa S. Cloning and sequence analysis of cDNA for rat corticotropin-releasing factor precursor. FEBS Letters 1985 191 63-66.
4. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D & Rivier C. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995 378 287-292.
5. Spina M, Merlo-Pich E, Chan RK, Basso AM, Rivier J, Vale W & Koob GF. Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science 1996 273 1561-1564.
6. Hsu SY & Hsueh AJ. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nature Medicine 2001 7 605-611.
7. Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, Vaughan J, Reyes TM, Gulyas J, Fischer W, Bilezikjian L, Rivier J, Sawchenko PE & Vale WW. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. PNAS 2001 98 7570-7575.
8. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, Hogenesch JB, Gulyas J, Rivier J, Vale WW & Sawchenko PE. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. PNAS 2001 98 2843-2848.
9. Turnbull AV, Vale W & Rivier C. Urocortin, a corticotropin-releasing factor-related mammalian peptide, inhibits edema due to thermal injury in rats. European Journal of Pharmacology 1996 303 213-216.
10. Parkes DG, Vaughan J, Rivier J, Vale W & May CN. Cardiac inotropic actions of urocortin in conscious sheep. American Journal of Physiology 1997 272 H2115-H2122.
11. Li C, Chen P, Vaughan J, Blount A, Chen A, Jamieson PM, Rivier J, Smith MS & Vale W. Urocortin III is expressed in pancreatic beta-cells and stimulates insulin and glucagon secretion. Endocrinology 2003 144 3216-3224.
12. Eckart K, Jahn O, Radulovic J, Tezval H, van Werven L & Spiess J. A single amino acid serves as an affinity switch between the receptor and the binding protein of corticotropin-releasing factor: implications for the design of agonists and antagonists. PNAS 2001 98 11142-11147.
13. Bale TL, Giordano FJ, Hickey RP, Huang Y, Nath AK, Peterson KL, Vale WW & Lee KF. Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization. PNAS 2002 99 7734-7739.
14. Chen R, Lewis KA, Perrin MH & Vale WW. Expression cloning of a human corticotropin-releasing-factor receptor. PNAS 1993 90 8967-8971.
15. Ross PC, Kostas CM & Ramabhadran TV. A variant of the human corticotropin-releasing factor (CRF) receptor: cloning, expression and pharmacology. Biochemical and Biophysical Research Communications 1994 205 1836-1842.
16. Grammatopoulos DK, Dai Y, Randeva HS, Levine MA, Karteris E, Easton AJ & Hillhouse EW. A novel spliced variant of the type 1 corticotropin- releasing hormone receptor with a deletion in the seventh transmembrane domain present in the human pregnant term myometrium and fetal membranes. Molecular Endocrinology 1999 13 2189-2202.
17. Pisarchik A & Slominski AT. Alternative splicing of CRH-R1 receptors in human and mouse skin: identification of new variants and their differential expression. Federation of American Societies for Experimental Biology 2001 15 2754-2756.
18. Liaw CW, Lovenberg TW, Barry G, Oltersdorf T, Grigoriadis DE & de Souza EB. Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid. Endocrinology 1996 137 72-77.
19. Valdenaire O, Giller T, Breu V, Gottowik J & Kilpatrick G. A new functional isoform of the human CRF2 receptor for corticotropin-releasing factor. Biochimica et Biophysics Acta 1997 1352 129-132.
20. Kostich WA, Chen A, Sperle K & Largent BL. Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2γ receptor. Molecular Endocrinology 1998 12 1077-1085.
21. Lovenberg TW, Chalmers DT, Liu C & De Souza EB. CRF2α and CRF2β receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology 1995 136 4139-4142.
22. Rivier J, Rivier C & Vale W. Synthetic competitive antagonists of corticotropin-releasing factor: effect on ACTH secretion in the rat. Science 1984 224 889-891.
23. Barquist E, Zinner M, Rivier J & Tache Y. Abdominal surgery-induced delayed gastric emptying in rats: role of CRF and sensory neurons. American Journal of Physiology 1992 262 G616-G620.
24. Nozu T, Martinez V, Rivier J & Tache Y. Peripheral urocortin delays gastric emptying: role of CRF receptor 2. American Journal of Physiology 1999 276 G867-G874.
25. Gilligan PJ & Li YW. Corticotropin-releasing factor antagonists: recent advances and exciting prospects for the treatment of human diseases. Current Opinion in Drug Discovery and Development 2004 7 487-497.
26. Zorrilla EP & Koob GF. The therapeutic potential of CRF1 antagonists for anxiety. Expert Opinion on Investigational Drugs 2004 13 799-828.
27. Arvanitis AG, Gilligan PJ, Chorvat RJ, Cheeseman RS, Christos TE, Bakthavatchalam R, Beck JP, Cocuzza AJ, Hobbs FW, Wilde RG, Arnold C, Chidester D, Curry M, He L, Hollis A, Klaczkiewicz J, Krenitsky PJ, Rescinito JP, Scholfield E, Culp S, De Souza EB, Fitzgerald L, Grigoriadis D, Tam SW & Shen HL. Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and - triazines. Journal of Medicinal Chemistry 1999 42 805-818.
28. Okuyama S, Chaki S, Kawashima N, Suzuki Y, Ogawa S, Nakazato A, Kumagai T, Okubo T & Tomisawa K. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. Journal of Pharmacology and Experimental Therapeutics 1999 289 926-935.
29. Griebel G, Perrault G & Sanger DJ. Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone. Psychopharmacology (Berl) 1998 138 55-66.
30. Piekut DT & Phipps B. Corticotropin-releasing factor - immunolabeled fibers in brain regions with localized kainate neurotoxicity. Acta Neuropathologica (Berl) 1999 98 622-628.
31. Mackay KB, Bozigian H, Grigoriadis DE, Loddick SA, Verge G & Foster AC. Neuroprotective effects of the CRF1 antagonist R121920 after permanent focal ischemia in the rat. Journal of Cerebral Blood Flow and Metabolism 2001 21 1208-1214.
32. Baram TZ, Chalmers DT, Chen C, Koutsoukos Y & De Souza EB. The CRF1 receptor mediates the excitatory actions of corticotropin-releasing factor (CRF) in the developing rat brain: in vivo evidence using a novel, selective, non-peptide CRF receptor antagonist. Brain Research 1997 770 89-95.
33. Theoharides TC, Spanos C, Pang X, Alferes L, Ligris K, Letourneau R, Rozniecki JJ, Webster E & Chrousos GP. Stress-induced intracranial mast cell degranulation: a corticotropin-releasing hormone-mediated effect. Endocrinology 1995 136 5745-5750.
34. Sarnyai Z, Shaham Y & Heinrichs SC. The role of corticotropin- releasing factor in drug addiction. Pharmacological Reviews 2001 53 209-243.
35. Shaham Y, Erb S, Leung S, Buczek Y & Stewart J. CP-154,526, a selective, non-peptide antagonist of the corticotropin-releasing factor1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats. Psychopharmacology (Berl) 1998 137 184-190.
36. Stinus L, Cador M, Zorrilla EP & Koob GF. Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats. Neuropsychopharmacology 2005 30 90-98.
37. Valdez GR & Koob GF. Allostasis and dysregulation of corticotropin-releasing factor and neuropeptide Y systems: implications for the development of alcoholism. Pharmacology Biochemistry and Behavior 2004 79 671-689.
38. Goeders NE & Clampitt DM. Potential role for the hypothalamo- pituitary-adrenal axis in the conditioned reinforcer-induced reinstatement of extinguished cocaine seeking in rats. Psychopharmacology (Berl) 2002 161 222-232.
39. Przegalinski E, Filip M, Frankowska M, Zaniewska M & Papla I. Effects of CP-154,526, a CRF1 receptor antagonist, on behavioral responses to cocaine in rats. Neuropeptides 2005 39 525-533.
40. Gravanis A & Margioris AN. The corticotropin-releasing factor (CRF) family of neuropeptides in inflammation: potential therapeutic applications. Current Medicinal Chemistry 2005 12 1503-1512.
41. Berkenbosch F, van Oers J, del Rey A, Tilders F & Besedovsky H. Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1. Science 1987 238 524-526.
42. Sapolsky R, Rivier C, Yamamoto G, Plotsky P & Vale W. Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. Science 1987 238 522-524.
43. Lumpkin MD. The regulation of ACTH secretion by IL-1. Science 1987 238 452-454.
44. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. New England Journal of Medicine 1995 332 1351-1362.
45. Karalis K, Sano H, Redwine J, Listwak S, Wilder RL & Chrousos GP. Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science 1991 254 421-423.
46. Webster EL, Lewis DB, Torpy DJ, Zachman EK, Rice KC & Chrousos GP. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 1996 137 5747-5750.
47. Radulovic M, Dautzenberg FM, Sydow S, Radulovic J & Spiess J. Corticotropin-releasing factor receptor 1 in mouse spleen: expression after immune stimulation and identification of receptor-bearing cells. Journal of Immunology 1999 162 3013-3021.
48. Venihaki M, Zhao J & Karalis KP. Corticotropin-releasing hormone deficiency results in impaired splenocyte response to lipopolysaccharide. Journal of Neuroimmunology 2003 141 3-9.
49. Venihaki M, Dikkes P, Carrigan A & Karalis KP. Corticotropin- releasing hormone regulates IL-6 expression during inflammation. Journal of Clinical Investigation 2001 108 1159-1166.
50. Webster EL, Barrientos RM, Contoreggi C, Isaac MG, Ligier S, Gabry KE, Chrousos GP, McCarthy EF, Rice KC, Gold PW & Sternberg EM. Corticotropin releasing hormone (CRH) antagonist attenuates adjuvant induced arthritis: role of CRH in peripheral inflammation. Journal of Rheumatology 2002 29 1252-1261.
51. Agelaki S, Tsatsanis C, Gravanis A & Margioris AN. Corticotropin-releasing hormone augments proinflammatory cytokine production from macrophages in vitro and in lipopolysaccharide-induced endotoxin shock in mice. Infection and Immunity 2002 70 6068-6074.
52. Gabry KE, Chrousos GP, Rice KC, Mostafa RM, Sternberg E, Negrao AB, Webster EL, McCann SM & Gold PW. Marked suppression of gastric ulcerogenesis and intestinal responses to stress by a novel class of drugs. Molecular Psychiatry 2002 7 474-483.
53. Uzuki M, Sasano H, Muramatsu Y, Totsune K, Takahashi K, Oki Y, Iino K & Sawai T. Urocortin in the synovial tissue of patients with rheumatoid arthritis. Clinical Science (London) 2001 100 577-589.
54. Crofford LJ, Sano H, Karalis K, Friedman TC, Epps HR, Remmers EF, Mathern P, Chrousos GP & Wilder RL. Corticotropin-releasing hormone in synovial fluids and tissues of patients with rheumatoid arthritis and osteoarthritis. Journal of Immunology 1993 151 1587-1596.
55. Kohno M, Kawahito Y, Tsubouchi Y, Hashiramoto A, Yamada R, Inoue KI, Kusaka Y, Kubo T, Elenkov IJ, Chrousos GP, Kondo M & Sano H. Journal of Clinical Endocrinology and Metabolism 2001 86 4344-4352.
56. Kawahito Y, Sano H, Mukai S, Asai K, Kimura S, Yamamura Y, Kato H, Chrousos GP, Wilder RL & Kondo M. Urocortin expression in synovium of patients with rheumatoid arthritis and osteoarthritis: relation to inflammatory activity. Gut 1995 37 544-551.
57. Saruta M, Takahashi K, Suzuki T, Torii A, Kawakami M & Sasano H. Journal of Clinical Endocrinology and Metabolism 2004 89 5352-5361.
58. Chatzaki E, Charalampopoulos I, Leontidis C, Mouzas IA, Tzardi M, Tsatsanis C, Margioris AN & Gravanis A. Urocortin in human gastric mucosa: relationship to inflammatory activity. Journal of Clinical Endocrinology and Metabolism 2003 88 478-483.
59. Kempuraj D, Papadopoulou N, Stanford EJ, Christodoulou S, Madhappan B, Sant GR, Solage K, Adams T & Theoharides TC. Increased numbers of activated mast cells in endometriosis lesions positive for corticotropin-releasing hormone and urocortin. American Journal of Reproductive Immunology 2004 52 267-275.
60. Scopa CD, Mastorakos G, Friedman TC, Melachrinou M, Merino MJ & Chrousos GP. Presence of immunoreactive corticotropin releasing hormone in thyroid lesions. American Journal of Pathology 1994 145 1159-1167.
61. Benou C, Wang Y, Imitola J, VanVlerken L, Chandras C, Karalis KP & Khoury SJ. Corticotropin-releasing hormone contributes to the peripheral inflammatory response in experimental autoimmune encephalomyelitis. Journal of Immunology 2005 174 5407-5413.
62. Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D & Conti P. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends in Pharmacological Sciences 2004 25 563-568.
63. Theoharides TC, Singh LK, Boucher W, Pang X, Letourneau R, Webster E & Chrousos G. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology 1998 139 403-413.
64. Cao J, Papadopoulou N, Kempuraj D, Boucher WS, Sugimoto K, Cetrulo CL & Theoharides TC. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. Journal of Immunology 2005 174 7665-7675.
65. Chrousos GP, Torpy DJ & Gold PW. Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system: clinical implications. Annals of Internal Medicine 1998 129 229-240.
66. Kalantaridou SN, Makrigiannakis A, Zoumakis E & Chrousos GP. Stress and the female reproductive system. Journal of Reproductive Immunology 2004 62 61-68.
67. Kalantaridou SN, Makrigiannakis A, Zoumakis E & Chrousos GP. Reproductive functions of corticotropin-releasing hormone. Research and potential clinical utility of antalarmins (CRH receptor type 1 antagonists). American Journal of Reproductive Immunology 2004 51 269-274.
68. Makrigiannakis A, Margioris AN, Le Goascogne C, Zoumakis E, Nikas G, Stournaras C, Psychoyos A & Gravanis A. Corticotropin-releasing hormone (CRH) is expressed at the implantation sites of early pregnant rat uterus. Life Sciences 1995 57 1869-1875.
69. Zoumakis E, Margioris AN, Stournaras C, Dermitzaki E, Angelakis E, Makrigiannakis A, Koumantakis E & Gravanis A. Corticotrophin-releasing hormone (CRH) interacts with inflammatory prostaglandins and interleukins and affects the decidualization of human endometrial stroma. Molecular Human Reproduction 2000 6 344-351.
70. Makrigiannakis A, Zoumakis E, Kalantaridou S, Coutifaris C, Margioris AN, Coukos G, Rice KC, Gravanis A & Chrousos GP. Corticotropin-releasing hormone promotes blastocyst implantation and early maternal tolerance. Nature Immunology 2001 2 1018-1024.
71. Bamberger AM, Minas V, Kalantaridou SN, Radde J, Sadeghian H, Loning T, Charalampopoulos I, Brummer J, Wagener C, Bamberger CM, Schulte HM, Chrousos GP & Makrigiannakis A. Corticotropin-releasing hormone modulates human trophoblast invasion through carcinoembryonic antigen-related cell adhesion molecule-1 regulation. American Journal of Pathology 2006 168 141-150.
72. Neulen J & Breckwoldt M. Placental progesterone, prostaglandins and mechanisms leading to initiation of parturition in the human. Experimental and Clinical Endocrinology 1994 102 195-202.
73. McLean M, Bisits A, Davies J, Woods R, Lowry P & Smith R. A placental clock controlling the length of human pregnancy. Nature Medicine 1995 1 460-463.
74. Challis JR. CRH, a placental clock and preterm labour. Nature Medicine 1995 1 416.
75. Chan EC, Falconer J, Madsen G, Rice KC, Webster EL, Chrousos GP & Smith RA. Corticotropin-releasing hormone type I receptor antagonist delays parturition in sheep. Endocrinology 1998 139 3357-3360.
76. Tache Y, Martinez V, Million M & Wang L. Stress and the gastrointestinal tract III. Stress-related alterations of gut motor function: role of brain corticotropin-releasing factor receptors. American Journal of Physiology. Gastrointestinal and Liver Physiology 2001 280 G173-G177.
77. Martinez V, Wang L, Rivier JE, Vale W & Tache Y. Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: role of CRF receptor subtypes 1 and 2. Journal of Pharmacology and Experimental Therapeutics 2002 301 611-617.
78. Million M, Maillot C, Saunders P, Rivier J, Vale W & Tache Y. Human urocortin II, a new CRF-related peptide, displays selective CRF(2)-mediated action on gastric transit in rats. American Journal of Physiology. Gastrointestinal and Liver Physiology 2002 282 G34-G40.
79. Miampamba M, Germano PM, Arli S, Wong HH, Scott D, Tache Y & Pisegna JR. Expression of pituitary adenylate cyclase-activating polypeptide and PACAP type 1 receptor in the rat gastric and colonic myenteric neurons. Regulatory Peptides 2002 105 145-154.
80. Saunders PR, Maillot C, Million M & Tache Y. Peripheral corticotropin-releasing factor induces diarrhea in rats: role of CRF1 receptor in fecal watery excretion. European Journal of Pharmacology 2002 435 231-235.
81. Muramatsu Y, Fukushima K, Iino K, Totsune K, Takahashi K, Suzuki T, Hirasawa G, Takeyama J, Ito M, Nose M, Tashiro A, Hongo M, Oki Y, Nagura H & Sasano H. Urocortin and corticotropin-releasing factor receptor expression in the human colonic mucosa. Peptides 2000 21 799-1809.
82. Chatzaki E, Crowe PD, Wang L, Million M, Tache Y & Grigoriadis DE. CRF receptor type 1 and 2 expression and anatomical distribution in the rat colon. Journal of Neurochemistry 2004 90 309-316.
83. Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, Webster EL, Atkinson AJ, Schulkin J, Contoreggi C, Chrousos GP, McCann SM, Suomi SJ, Higley JD & Gold PW. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proceedings of the National Academy of Sciences of the United States of America 2000 97 6079-6084.
84. Lu L, Liu D, Ceng X & Ma L. Differential roles of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence. European Journal of Neuroscience 2000 12 4398-4404.
85. Maillot C, Million M, Wei JY, Gauthier A & Tache Y. Peripheral corticotropin-releasing factor and stress-stimulated colonic motor activity involve type 1 receptor in rats. Gastroenterology 2000 119 1569-1579.
86. Funada M, Hara C & Wada K. Involvement of corticotropin-releasing factor receptor subtype 1 in morphine withdrawal regulation of the brain noradrenergic system. European Journal of Pharmacology 2001 430 277-281.
87. Martinez V & Tache Y. Role of CRF receptor 1 in central CRF-induced stimulation of colonic propulsion in rats. Brain Research 2001 893 29-35.
88. Bale TL, Picetti R, Contarino A, Koob GF, Vale WW & Lee KF. Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior. Journal of Neuroscience 2002 22 193-199.
89. Martinez V, Wang L, Rivier J, Grigoriadis D & Tache Y. Central CRF, urocortins and stress increase colonic transit via CRF1 receptors while activation of CRF2 receptors delays gastric transit in mice. Journal of Physiology 2004 556 221-234.
90. Gue M, Del Rio-Lacheze C, Eutamene H, Theodorou V, Fioramonti J & Bueno L. Stress-induced visceral hypersensitivity to rectal distension in rats: role of CRF and mast cells. Neurogastroenterology and Motility 1997 9 271-279.
91. Greenwood-Van Meerveld B, Johnson AC, Foreman RD & Linderoth B. Spinal cord stimulation attenuates visceromotor reflexes in a rat model of post-inflammatory colonic hypersensitivity. Autonomic Neuroscience 2005 122 69-76.
92. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D & Rivier C. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995 378 287-292.
93. Hsu SY & Hsueh AJW. Human stesscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nature Medicine 2001 7 605-611.
94. Pelleymounter MA, Joppa M, Carmouche M, Cullen MJ, Brown B, Murphy B, Grigoriadis DE, Ling N & Foster AC. Role of corticotropin-releasing factor (CRF) receptors inthe anorexic syndrome induced by CRF. Journal of Pharmacology and Experimental Therapeutics 2002 293 799-806.
95. Vetter DE, Li C, Zhao L, Contarino A, Liberman MC, Smith GW, Marchuk Y, Koob GF, Heinemann SF, Vale W & Lee KF. Urocortin-deficient mice show hearing impairment and increased anxiety-like behavior. Nature Genetics 2002 31 363-369.
96. Parkes GD & May CN. Urocortin: a novel player in cardiac control. News in Physiological Sciences 2000 15 264-268.
97. Gold PW & Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: high versus low CRH/NE States. Molecular Psychiatry 2002 7 254-275.
98. Vgontzas AN, Vela-Bueno A & Chrousos GP. Endocrine disorders and sleep. In Sleep Medicine, pp 477-487. Ed. TL Lee-Chiong, Philadelphia, PA: Hanley & Belfus, 2002.